TY - JOUR
T1 - Global epidemiology of systemic lupus erythematosus
AU - Barber, Megan R.W.
AU - Drenkard, Cristina
AU - Falasinnu, Titilola
AU - Hoi, Alberta
AU - Mak, Anselm
AU - Kow, Nien Yee
AU - Svenungsson, Elisabet
AU - Peterson, Jonna
AU - Clarke, Ann E.
AU - Ramsey-Goldman, Rosalind
N1 - Funding Information:
A.E.C. has received consulting fees from AstraZeneca, Exagen Diagnostics and GlaxoSmithKline. A.M. has received consulting fees from Janssen and research grants from GlaxoSmithKline and Janssen. C.D. is supported by a GlaxoSmithKline award (ID 0000048412). E.S. has received honoraria from Janssen and Lilly. R.R.-G. has received research grants from Exagen Diagnostics and consulting fees from Thermo Fisher Scientific and Aurinia Pharmaceuticals. A.H. has received honoraria from AstraZeneca, Janssen and AbbVie, and research grant from Merck Serono. M.R.W.B has received consulting fees from AbbVie, Janssen, GlaxoSmithKline and Sanofi Genzyme. All other authors declare no competing interests.
Publisher Copyright:
© 2021, Springer Nature Limited.
PY - 2021/9
Y1 - 2021/9
N2 - Systemic lupus erythematosus (SLE) is an autoimmune disease with protean manifestations that predominantly affects young women. Certain ethnic groups are more vulnerable than others to developing SLE and experience increased morbidity and mortality. Reports of the global incidence and prevalence of SLE vary widely, owing to inherent variation in population demographics, environmental exposures and socioeconomic factors. Differences in study design and case definitions also contribute to inconsistent reporting. Very little is known about the incidence of SLE in Africa and Australasia. Identifying and remediating such gaps in epidemiology is critical to understanding the global burden of SLE and improving patient outcomes. Mortality from SLE is still two to three times higher than that of the general population. Internationally, the frequent causes of death for patients with SLE include infection and cardiovascular disease. Even without new therapies, mortality can potentially be mitigated with enhanced quality of care. This Review focuses primarily on the past 5 years of global epidemiological studies and discusses the regional incidence and prevalence of SLE and top causes of mortality.
AB - Systemic lupus erythematosus (SLE) is an autoimmune disease with protean manifestations that predominantly affects young women. Certain ethnic groups are more vulnerable than others to developing SLE and experience increased morbidity and mortality. Reports of the global incidence and prevalence of SLE vary widely, owing to inherent variation in population demographics, environmental exposures and socioeconomic factors. Differences in study design and case definitions also contribute to inconsistent reporting. Very little is known about the incidence of SLE in Africa and Australasia. Identifying and remediating such gaps in epidemiology is critical to understanding the global burden of SLE and improving patient outcomes. Mortality from SLE is still two to three times higher than that of the general population. Internationally, the frequent causes of death for patients with SLE include infection and cardiovascular disease. Even without new therapies, mortality can potentially be mitigated with enhanced quality of care. This Review focuses primarily on the past 5 years of global epidemiological studies and discusses the regional incidence and prevalence of SLE and top causes of mortality.
UR - http://www.scopus.com/inward/record.url?scp=85111842689&partnerID=8YFLogxK
U2 - 10.1038/s41584-021-00668-1
DO - 10.1038/s41584-021-00668-1
M3 - Review Article
C2 - 34345022
AN - SCOPUS:85111842689
SN - 1759-4790
VL - 17
SP - 515
EP - 532
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
IS - 9
ER -